Vanda Pharmaceuticals Files 8-K Report
Ticker: VNDA · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: VNDA
TL;DR
Vanda Pharma filed an 8-K, standard procedure, no major news yet.
AI Summary
On June 13, 2024, Vanda Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Washington, DC.
Why It Matters
This 8-K filing indicates that Vanda Pharmaceuticals is providing updates or submitting required documentation to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- June 13, 2024 (date) — Date of Report
- 20240613 (date) — Conformed Period of Report
- 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 (location) — Principal executive offices
- 001-34186 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Vanda Pharmaceuticals Inc.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine updates or submissions to the SEC.
When was this 8-K report filed?
The report was filed on June 13, 2024.
What is Vanda Pharmaceuticals Inc.'s state of incorporation?
Vanda Pharmaceuticals Inc. is incorporated in Delaware.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Does this filing disclose any specific new material events or transactions?
Based on the provided text, no specific new material events or transactions are detailed; it appears to be a standard filing.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-13 16:38:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d843445d8k.htm (8-K) — 26KB
- d843445dex991.htm (EX-99.1) — 7KB
- g843445img01.jpg (GRAPHIC) — 9KB
- 0001193125-24-160755.txt ( ) — 204KB
- vnda-20240613.xsd (EX-101.SCH) — 4KB
- vnda-20240613_def.xml (EX-101.DEF) — 13KB
- vnda-20240613_lab.xml (EX-101.LAB) — 22KB
- vnda-20240613_pre.xml (EX-101.PRE) — 14KB
- d843445d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Vanda Pharmaceuticals Inc. dated June 13, 2024, Confirming Receipt of Revised Unsolicited Takeover Proposal from Future Pak. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 13, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary